<DOC>
	<DOCNO>NCT02543112</DOCNO>
	<brief_summary>This Long-term Access Programme ( LAP ) aim support provision mepolizumab , commercially available , eligible subject severe asthma participate GSK-sponsored mepolizumab clinical study 200862 200363 . Eligible subject initiate mepolizumab within 6-month period follow individual subject 's last scheduled visit precede clinical study . For subject benefit versus risk assess throughout study support continue treatment mepolizumab .</brief_summary>
	<brief_title>A Long-term Access Programme Subjects With Severe Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Subject participate GSKsponsored asthma clinical study mepolizumab specify Study 200862 200363 Subject either : complete treatment period mepolizumab asthma clinical study originally enrol subject withdrawn study treatment prematurely mepolizumab asthma clinical study originally enrol subject complete study assessment study visit would end respective treatment period . The treat physician request mepolizumab Longterm Access Programme consider benefit treatment mepolizumab outweigh risk individual subject . To eligible mepolizumab treatment Longterm Access Programme , females childbearing potential ( FCBP ) must commit consistent correct use acceptable method birth control , begin consent , duration treatment mepolizumab 4 month last mepolizumab administration . The subject consent receive treatment mepolizumab Longterm Access Programme . In case paediatric subject eligible parent ( ) /guardian give write informed consent prior child 's participation study . If applicable , subject must able willing give assent take part study accord local requirement . A current malignancy history cancer remission le 12 month ( Subjects localize carcinoma ( i.e. , basal squamous cell ) skin resect cure exclude ) . Subject clinically significant medical condition uncontrolled standardofcare therapy associate asthma , e.g. , unstable liver disease , uncontrolled cardiovascular disease , ongoing active infectious disease require systemic treatment . Subject pregnant breastfeeding . Subjects consider continue treatment plan become pregnant course treatment mepolizumab . Subject know allergy intolerance monoclonal antibody biologic therapy include mepolizumab . Subject adverse event ( serious nonserious ) consider related study treatment whilst participate clinical study mepolizumab result permanent withdrawal study treatment . Subject receive treatment another biological therapy monoclonal antibody therapy intravenous ( IV ) immunoglobulin ( Ig ) therapy . Subjects receive treatment investigational drug within past 30 day 5 terminal phase halflives drug whichever longer , prior initiation mepolizumab treatment Longterm Access Programme ( also include investigational formulation market product ) . Subject currently participate interventional clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>mepolizumab</keyword>
	<keyword>severe asthma</keyword>
	<keyword>LAP</keyword>
	<keyword>benefit versus risk</keyword>
</DOC>